Influx Health.

Why is Influx Healthtech Ltd falling/rising?

As of 24-Aug, Influx Healthtech Ltd's stock price is currently at 300.05, reflecting a 2.76% increase and outperforming the Sensex. Despite a decline in investor participation, the stock shows strong bullish trends and significant gains over various time frames.

As of 24-Aug, Influx Healthtech Ltd's stock price is rising, currently at 300.05, which reflects an increase of 8.05 or 2.76%. This upward movement can be attributed to several factors. Over the past week, the stock has gained 0.72%, while the benchmark Sensex has decreased by 0.28%, indicating that Influx Healthtech is outperforming the broader market. Additionally, the stock has shown strong performance over longer periods, with a year-to-date increase of 32.71% compared to a decline of 7.31% in the Sensex, and an impressive 81.63% rise over the past year against a slight drop in the benchmark.<BR><BR>Moreover, the stock is currently trading higher than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which suggests a strong bullish trend. It is also close to its 52-week high, being only 4.98% away from the peak of Rs 315. However, it is worth noting that there has been a decline in investor participation, with delivery volume dropping by 45.74% against the 5-day average, which could indicate a potential concern for future trading activity. Despite this, the overall positive performance metrics contribute to the stock's rising price.

Which are the latest news on Influx Health.?

What does Influx Health. do?

Influx Healthtech Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, with a market cap of INR 689 Cr. It has no recent sales or profit reports, a P/E ratio of 33.00, and a return on equity of 20.39%.

Overview: <BR>Influx Healthtech Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>Details regarding the incorporation year and any status changes are not available. Additionally, there are no sales and profit reports for the latest quarter.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 689 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 33.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.27 <BR>Return on Equity (ROE): 20.39% <BR>Price-to-Book: 6.83<BR><BR>Contact Details: <BR>Registrar Address: Not available <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Influx Health.?

Influx Health's peers include Wanbury, Kopran, Anuh Pharma, Anlon Healthcare, Kilitch Drugs, Zim Laboratories, Bafna Pharma, Shree Ganesh Rem, and Amanta Healthcar. Influx Health has a good growth rating and an excellent capital structure, with a 1-year return of 103.16%.

Peers: The peers of Influx Health are Wanbury, Kopran, Anuh Pharma, Anlon Healthcare, Kilitch Drugs, Zim Laboratories, Bafna Pharma, Shree Ganesh Rem, and Amanta Healthcar.<BR><BR>Quality Snapshot: Excellent management risk is observed at Anuh Pharma and Kilitch Drugs, while Average management risk is found at Wanbury, Kopran, Anlon Healthcare, Influx Health, Zim Laboratories, Shree Ganesh Rem, and Amanta Healthcar, and the rest. Growth is Excellent at Anlon Healthcare and Kilitch Drugs, Good at Influx Health, and Average at Wanbury, Kopran, Anuh Pharma, Zim Laboratories, Shree Ganesh Rem, and the rest. Capital Structure is Excellent at Anuh Pharma and Influx Health, Good at Kopran, Anlon Healthcare, Kilitch Drugs, and Bafna Pharma, and Below Average at Amanta Healthcar, and the rest.<BR><BR>Return Snapshot: Bafna Pharma has the highest 1-year return at 164.32%, while Anuh Pharma has the lowest at -12.89%. Influx Health's 1-year return of 103.16% is significantly higher than Anuh Pharma's. Additionally, Amanta Healthcar and Anuh Pharma have negative six-month returns.

How big is Influx Health.?

As of 14th August, Influx Healthtech Ltd has a market capitalization of 692.00 Cr, classifying it as a Micro Cap company, with no available financial data for Net Sales or Net Profit for the latest four quarters. The balance sheet as of March 2025 shows Shareholder's Funds of 36.15 Cr and Total Assets of 70.12 Cr.

As of 14th August, <BR><BR>Market Cap: Influx Healthtech Ltd has a market capitalization of 692.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales or Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 36.15 Cr and Total Assets valued at 70.12 Cr.

Is Influx Health. overvalued or undervalued?

As of December 3, 2025, Influx Health is fairly valued with a PE ratio of 40.22, an EV to EBITDA of 24.18, and a ROCE of 33.05%, positioning it between peers Sun Pharma and Divi's Lab in terms of valuation.

As of 3 December 2025, Influx Health has moved from an attractive to a fair valuation grade. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 40.22, an EV to EBITDA of 24.18, and a ROCE of 33.05%. <BR><BR>In comparison to peers, Influx Health's PE ratio is higher than Sun Pharma's 37.51 and significantly lower than Divi's Lab's 68.92, which is categorized as very expensive. While the company has shown strong returns over the past week and month, outperforming the Sensex, its current valuation suggests that it is neither undervalued nor overvalued in the current market context.

How has been the historical performance of Influx Health.?

Influx Health showed positive financial performance from March 2024 to March 2025, with net sales increasing from 99.97 Cr to 104.85 Cr, operating profit rising from 16.96 Cr to 20.56 Cr, and profit after tax growing from 11.13 Cr to 13.37 Cr, despite a decrease in cash flow from operating activities. Total assets and liabilities both grew significantly, indicating balanced growth.

Answer:<BR>The historical performance of Influx Health shows a positive trend in key financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Influx Health's net sales increased from 99.97 Cr in March 2024 to 104.85 Cr in March 2025, reflecting a growth in total operating income from 99.97 Cr to 104.85 Cr. The raw material cost decreased slightly from 65.27 Cr to 63.41 Cr, while employee costs rose from 7.04 Cr to 8.79 Cr. Total expenditure, excluding depreciation, increased from 83.01 Cr to 84.29 Cr. Operating profit (PBDIT) rose from 16.96 Cr to 20.56 Cr, leading to an operating profit margin improvement from 16.97% to 19.61%. Profit before tax also increased from 14.93 Cr to 17.88 Cr, with profit after tax rising from 11.13 Cr to 13.37 Cr, resulting in a PAT margin increase from 11.13% to 12.75%. The company's total assets grew significantly from 40.82 Cr to 70.12 Cr, while total liabilities increased from 40.82 Cr to 70.12 Cr, indicating a balanced growth in both assets and liabilities. Cash flow from operating activities decreased from 8.00 Cr to 7.00 Cr, contributing to a net cash outflow of 1.00 Cr in March 2025, compared to no outflow in the previous year. Overall, Influx Health demonstrated a strong performance with improvements in profitability and asset growth.